Want to see TFX full AI Analyst Report?
Top Page
Teleflex
(NYSE:TFX)
Select Model
Select Model
Rating:58Neutral
Price Target:
$145.00
▲(9.77% Upside)
Action:Reiterated
Date:08/04/26
TFX scores as a mid-range setup driven primarily by weak recent profitability and contracting revenue (biggest negative), partially offset by resilient cash generation and improved leverage. Technicals are constructive with price above key moving averages and positive MACD, while valuation is muted due to a negative P/E and a modest dividend. Guidance and corporate actions (divestiture proceeds, debt paydown and planned buybacks) provide support, but margin/recall/tariff and execution risks keep the score capped.
Positive Factors
OEM divestiture completed
Closing the OEM sale materially refocuses Teleflex on core medical franchises and provides durable capital. The expected after-tax proceeds are earmarked to repay ~$800M of debt and complete a $1B buyback, improving leverage, capital allocation flexibility and balance-sheet optionality over the next few quarters.
Negative Factors
Severe profitability deterioration
A deep TTM net loss and negative EBITDA reflect substantial below‑the‑line charges and weakened operating performance. Persistent weak profitability reduces retained earnings, depresses ROE, and can limit reinvestment or make future margin recovery more difficult if one-off charges become recurring.
Read all positive and negative factors
Positive Factors
Negative Factors
OEM divestiture completed
Closing the OEM sale materially refocuses Teleflex on core medical franchises and provides durable capital. The expected after-tax proceeds are earmarked to repay ~$800M of debt and complete a $1B buyback, improving leverage, capital allocation flexibility and balance-sheet optionality over the next few quarters.
Read all positive factors
Teleflex Key Performance Indicators (KPIs)
Any
Revenue by Segment
Highlights income from different business units, showcasing which segments drive growth and profitability, and indicating strategic focus areas.
Highlights income from different business units, showcasing which segments drive growth and profitability, and indicating strategic focus areas.
Data provided by:
The Fly
The FlyTeleflex (TFX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$6.05B
Dividend Yield0.99%
Average Volume (3M)423.26K
Price to Earnings (P/E)―
Beta (1Y)0.56
Revenue Growth-6.61%
EPS Growth-812.37%
CountryUS
Employees15,500
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-22.80
Shares Outstanding44,270,210
10 Day Avg. Volume405,055
30 Day Avg. Volume423,264
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.74
Price to Sales (P/S)2.73
P/FCF Ratio22.19
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$150.44Price Target Upside13.89% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)6.68
Revenue Forecast (FY)$2.29B
Teleflex Business Overview & Revenue Model
Company Description
Teleflex Incorporated is a global medical technology company dedicated to designing, developing, manufacturing, and distributing single-use medical devices. These products are crucial for diagnostic and therapeutic procedures, particularly within ...
How the Company Makes Money
Teleflex makes money primarily by selling medical devices and related consumables to healthcare providers. Its revenue model is largely product-based, with significant recurring demand driven by single-use (disposable) devices used in routine and ...
Teleflex Earnings Call Summary
Earnings Call Date:May 07, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 06, 2026
Earnings Call Sentiment Neutral
Balanced call: management reported solid pro forma revenue growth, strategic progress on M&A, a large capital return plan and promising clinical trial enrollment, but results were tempered by significant margin pressure (470–510 bps declines), remediation and recall costs, stranded costs from planned separations, higher interest expense and temporary integration/disruption in Interventional. Management positioned many negatives as largely transient and highlighted expected improvement beginning in 2027.Positive Updates
Revenue Growth — Q1 2026
Total continuing operations revenue of $548.3 million in Q1 2026, up 32.3% year-over-year on a GAAP basis and up 5.1% on a pro forma adjusted constant currency basis.
Negative Updates
Margin Compression — Q1 2026
Adjusted gross margin declined by 470 basis points to 61.4% year-over-year and adjusted operating margin declined by 510 basis points to 18.1%, driven by tariffs, quality remediation charges, higher logistics/distribution costs and the lower-margin Vascular Intervention acquisition.
Read all updates
Q1-2026 Updates
Positive
Negative
Revenue Growth — Q1 2026
Total continuing operations revenue of $548.3 million in Q1 2026, up 32.3% year-over-year on a GAAP basis and up 5.1% on a pro forma adjusted constant currency basis.
Read all positive updates
Company Guidance
Teleflex reiterated 2026 continuing‑operations guidance calling for pro forma adjusted constant‑currency revenue growth of 4.5%–5.5%, adjusted EPS of $6.25–$6.55, and an adjusted operating margin of ~19% (which includes roughly $90M of stranded costs and assumes R&D at ~8% of sales); management estimates an underlying steady‑state adjusted operating margin of ~23% (≈400 bps higher) once TSA/MSA benefits and stranded‑cost mitigation occur. The company expects full‑year net interest expense of ~$105M, a tax rate of ~13.5%, an FX headwind of about $14M, and assumes no 2026 benefit from TSA/MSA fees or tariff refunds in the guidance; it also reiterated plans to receive ~ $1.8B of after‑tax proceeds from the divestitures (expected to close in H2 2026, OEM in Q3), to repurchase up to $1B of stock (opportunistically beginning in Q2), to repay ~$800M of debt, noted Q1 net leverage around 2.5x, and disclosed a multiyear restructuring targeting ~ $50M of annual pretax savings by mid‑2028; guidance excludes the acute care, interventional urology and OEM businesses.Teleflex Financial Statement Overview
Summary
Income Statement
32
Negative
Balance Sheet
58
Neutral
Cash Flow
67
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.81B | 1.99B | 3.05B | 2.97B | 2.79B | 2.81B |
| Gross Profit | 1.50B | 1.12B | 1.70B | 1.65B | 1.53B | 1.55B |
| EBITDA | -88.47M | 302.51M | 433.62M | 761.21M | 730.77M | 853.80M |
| Net Income | -1.01B | -905.64M | 69.67M | 356.33M | 363.14M | 485.37M |
Balance Sheet | ||||||
| Total Assets | 6.78B | 6.95B | 7.10B | 7.53B | 6.93B | 6.87B |
| Cash, Cash Equivalents and Short-Term Investments | 309.41M | 393.26M | 306.16M | 222.85M | 292.03M | 445.08M |
| Total Debt | 2.69B | 2.73B | 1.76B | 1.93B | 1.83B | 1.97B |
| Total Liabilities | 3.70B | 3.82B | 2.82B | 3.09B | 2.91B | 3.12B |
| Stockholders Equity | 3.08B | 3.12B | 4.28B | 4.44B | 4.02B | 3.75B |
Cash Flow | ||||||
| Free Cash Flow | 249.02M | 245.44M | 509.31M | 419.20M | 262.95M | 579.80M |
| Operating Cash Flow | 314.25M | 340.68M | 635.74M | 510.64M | 342.14M | 651.42M |
| Investing Cash Flow | -895.18M | -849.19M | -99.36M | -621.23M | -257.94M | 156.74M |
| Financing Cash Flow | 626.08M | 611.54M | -421.93M | 38.54M | -217.51M | -715.82M |
Teleflex Technical Analysis
Positive
132.10
Price Trends
131.31
Positive
126.73
Positive
120.89
Positive
Market Momentum
1.78
Negative
62.24
Neutral
75.58
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TFX, the sentiment is Positive. The current price of 132.1 is below the 20-day moving average (MA) of 134.20, above the 50-day MA of 131.31, and above the 200-day MA of 120.89, indicating a bullish trend. The MACD of 1.78 indicates Negative momentum. The RSI at 62.24 is Neutral, neither overbought nor oversold. The STOCH value of 75.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TFX.
Teleflex Risk Analysis
Teleflex disclosed 34 risk factors in its most recent earnings report. Teleflex reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Teleflex Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | $5.08B | 34.70 | 9.07% | ― | 10.51% | 20.67% | |
75 Outperform | $2.32B | 36.71 | 16.19% | 0.94% | 13.27% | 36.99% | |
64 Neutral | $3.89B | 41.93 | 11.32% | ― | -1.97% | -38.95% | |
63 Neutral | $4.21B | 90.11 | 2.19% | ― | -10.76% | ― | |
61 Neutral | $6.04B | -35.36 | -2.61% | ― | 8.85% | 37.70% | |
58 Neutral | $6.05B | -6.00 | -28.27% | 1.03% | -6.61% | -812.37% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
TFX
Teleflex
140.12
26.57
23.40%
HAE
Haemonetics
85.38
9.27
12.18%
ICUI
ICU Medical
171.96
42.94
33.28%
LMAT
Lemaitre Vascular
105.78
20.96
24.71%
MMSI
Merit Medical Systems
85.82
1.33
1.57%
BLCO
Bausch + Lomb Corporation
16.68
2.24
15.51%
Teleflex Corporate Events
Business Operations and StrategyStock BuybackM&A Transactions
Teleflex Completes OEM Business Sale to Montagu, Kohlberg
Positive
Aug 3, 2026
On August 3, 2026, Teleflex completed the previously announced sale of its Original Equipment Manufacturing and Development Services business to an affiliate of Montagu and Kohlberg for $1.5 billion in cash. The transaction, conducted via Lotus US...
Business Operations and StrategyPrivate Placements and Financing
Teleflex Issues New Senior Notes to Strengthen Capital Structure
Positive
Jun 15, 2026
On June 15, 2026, Teleflex issued $500 million of 5.875% senior notes due January 15, 2032, which pay interest semi-annually starting January 15, 2027, and rank as general unsecured senior obligations alongside its existing 4.25% senior notes due ...
Executive/Board Changes
Teleflex grants special RSU award to interim CEO
Positive
Jun 9, 2026
Teleflex’s independent directors approved on June 8, 2026 a special restricted stock unit award with a grant date fair value of $600,000 for Stuart A. Randle, recognizing his significant contributions as Interim President and Chief Executive...
Business Operations and StrategyPrivate Placements and Financing
Teleflex Prices $500 Million Senior Notes for Refinancing
Positive
Jun 2, 2026
On June 1, 2026, Teleflex announced it had priced a private offering of $500 million in 5.875% senior notes due 2032 at par, with closing expected around June 15, 2026, subject to customary conditions. The notes will be guaranteed by certain exist...
Private Placements and Financing
Teleflex Announces $500 Million Senior Notes Private Offering
Positive
Jun 1, 2026
On June 1, 2026, Teleflex Incorporated announced the launch of a private offering of $500 million in senior notes due 2032, with pricing terms such as the interest rate to be set at a later date. The notes will be guaranteed by certain existing an...
Business Operations and StrategyPrivate Placements and Financing
Teleflex Establishes New Multi-Bank Credit Agreement Facility
Positive
May 27, 2026
On May 26, 2026, Teleflex entered into a new multi-bank credit agreement that refinances its November 2022 facility and establishes a capital structure anchored by a $1.0 billion five-year revolving credit line, a $500 million term A-1 loan and a ...
Executive/Board ChangesShareholder Meetings
Teleflex Shareholders Endorse Directors, Pay and Auditor
Positive
May 20, 2026
Teleflex held its 2026 annual meeting of stockholders on May 15, 2026, at which shareholders voted on the election of seven directors to one-year terms, an advisory resolution on executive compensation and the ratification of PricewaterhouseCooper...
Business Operations and StrategyExecutive/Board ChangesStock BuybackFinancial DisclosuresM&A Transactions
Teleflex Posts Q1 Results, Maintains 2026 Outlook, Plans Buyback
Neutral
May 7, 2026
Teleflex reported first-quarter 2026 results on May 7, 2026, with revenue from continuing operations rising 32.3% year over year to $548.3 million, or 5.1% on a pro forma adjusted constant currency basis, while GAAP diluted EPS from continuing ope...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.